The aim of this multicenter , randomized , open-label phase II trial was to assess the efficacy of ixabepilone as monotherapy , and the combination of ixabepilone with cetuximab , as first-line treatment in patients with triple-negative locally advanced nonresectable and/or metastatic breast cancer .